Gian Antonio Dompé is born in Bene Vagienna, Italy. From early childhood he has a passion for chemical and pharmaceutical sciences, that will lead him and his family in the pursuit of studying and formulating medicines.

Gian Antonio's son, Onorato Dompé and his partner found the Dompé-Adami laboratory in via Pantano in Milan.


Onorato purchases the Farmacia Centrale located in piazza della Scala - possibly the most important pharmacy in Milan. Over the following years he expands, establishing pharmacies in piazza Missori, Milan, Palermo and Ponte Chiasso, Switzerland.

Onorato founds the Farmacie italo-inglesi, which operates according to the British Pharmacopoeia standards.
Their formulations lead to a transformation in how pharmacies are run and a chain of shops are established in major cities across Italy.
Dompé became the first in Italy to introduce innovative methodologies, creating new drugs such as "Ferro Indoloro". At the time it was the only remedy for Anemia.

Onorato acquires a building in via San Martino 12, Milan. He lives there for the rest of his life, with his family and company, exploring new pharmaceutical preparations.

Onorato’s son, Franco Dompé, turns his father's work into an industry after graduating in Chemistry and Pharmacy at the University of Pavia in 1936. He establishes a laboratory at Via Bocconi 9, Milan. This is the start of Dompé farmaceutici.

Franco's company continues to grow despite World War II, and he moves the company to via San Martino 12, the Dompé global headquarters today in Milan.

Dompé farmaceutici establishes a reputation for the production of medicines, establishing a major production plant that was inaugurated in the presence of Monsignor Ildefonso Schuster, Cardinal of Milan.

Dompé sponsors and provides medical services to the Cortina d'Ampezzo Olympics.

Sergio Dompé launches a new strategy: investment in research and a focus on targeted therapeutic areas including anti-inflammatory, osteoarticular and respiratory diseases.

Rita Levi Montalcini receives the Nobel Prize in Physiology of Medicine for her discovery of the Nerve Growth Factor (NGF). Her work will go on to serve as a foundation for the development of recombinant human NGF, the first product that Dompé will launch in the US.

Credit to: "Presidenza della Repubblica"

Dompé Biotec is born, a key hub for biotechnological innovation in Italy and Europe.

The Dompé production hub is launched in L’Aquila, Italy, specializing in the production of oral, liquid and granular formulations.

In L’Aquila, Dompé opens a state-of-the-art biotech plant for the production of recombinant proteins.

In Italy, Biogen Dompé, a joint venture between Biogen Idec and Dompé is launched. Biogen Dompé is dedicated to finding new therapeutic solutions for multiple sclerosis.

In Italy, Amgen Dompé is established, a joint venture between Amgen and Dompé focused on the development of drugs for oncology and nephrology.

Dompé creates the Q-rare division, with the goal of offering innovative therapeutic solutions for the treatment of Orphan diseases with high unmet need.

Dompé acquires the rights to study, produce, and market Nerve Growth Factor (NGF), the protein theorized as a treatment for rare ophthalmic diseases.
This will become the first approved therapeutic application from the studies that won Rita Levi Montalcini the Nobel Prize.
Dompé also acquires more than 30% of Philogen, a biotech company involved in the development of oncological drugs.

Dompé expands its facilities for biotechnology research and production in the L’Aquila biotech plant


Dompé opens new headquarters in Milan and completes the acquisition of Anabasis - the Italian company developing innovative treatments for eye diseases.

Dompé takes over the Pharma division of Gruppo farmaceutico Bracco, establishing a foothold in the Primary Care market in Italy.

Dompé launches Dompé Primary to develop and distribute Prescription drugs and OTC products, dietary supplements, medical devices and cosmetics in Europe.

In July, the European Commission authorizes marketing of Cenegermin rhNGF-based eye drops, the first biotech drug authorized for the treatment of Neurotrophic Keratitis, in the E.U.

In August, the FDA approves rhNGF-based eye drops (cenegermin-bkbj) for the treatment of NK. The first application of human nerve growth factor approved by the FDA.
Dompé opens its San Francisco bay area office to expand operations in the US market.